NICE guidance - dapagliflozin for treating chronic kidney disease

Last edited 03/2022 and last reviewed 07/2023

Dapagliflozin for treating chronic kidney disease

NICE suggest that (1):

  • Dapagliflozin is recommended as an option for treating chronic kidney disease (CKD) in adults. It is recommended only if:
    • it is an add-on to optimised standard care including the highest tolerated licensed dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), unless these are contraindicated, and
    • people have an estimated glomerular filtration rate (eGFR) of 25 ml/min/1.73 m2 to 75 ml/min/1.73 m2 at the start of treatment and:
      • have type 2 diabetes or
      • have a urine albumin-to-creatinine ratio (uACR) of 22.6 mg/mmol or more

Study evidence supporting use of dapagliflozin for chronic kidney disease comes from the DAPA-CKD trial where (2,3):

  • dapagliflozin significantly reduced the risk of kidney failure, CV death or HF hospitalization, and all-cause mortality in patients with CKD, with and without T2DM, compared to placebo

Reference:

Related pages:

DAPA CKD